Xydakis Dimitris, Papadogiannakis Apostolos, Sfakianaki Maria, Kostakis Konstantinos, Stylianou Konstantinos, Petrakis Ioannis, Ergini Antonaki, Voskarides Konstantinos, Dafnis Eugeneios
Nephrology Department, Venizeleio Hospital, 71409 Heraklion, Crete, Greece.
Nephrology Department, University Hospital of Heraklion, Voutes, 71100 Heraklion, Crete, Greece.
ISRN Nephrol. 2012 Dec 24;2013:184527. doi: 10.5402/2013/184527. eCollection 2013.
Residual Renal function (RRF) has an important role in the overall morbidity and mortality in hemodialysis patients. The role of angiotensin-converting enzyme inhibitor (ACEi) in preserving renal function in chronic proteinuric nephropathies is well documented. We test the hypothesis that enalapril (an ACEi) slows the rate of decline of RRF in patients starting hemodialysis. A prospective, randomized open-label study was carried out. 42 patients were randomized in two groups either in treatment with enalapril or no treatment at all. Our study has proven that enalapril has a significant effect on preserving residual renal function in patients starting dialysis at least during the first 12 months from the initiation of the hemodialysis. Further studies are necessary in order to investigate the potential long-term effect of ACEi on residual renal function and on morbidity and mortality in patients starting hemodialysis.
残余肾功能（RRF）在血液透析患者的总体发病率和死亡率中起着重要作用。血管紧张素转换酶抑制剂（ACEi）在慢性蛋白尿性肾病中保护肾功能的作用已有充分记录。我们检验了依那普利（一种ACEi）可减缓开始血液透析患者RRF下降速率的假设。开展了一项前瞻性、随机开放标签研究。42例患者被随机分为两组，一组接受依那普利治疗，另一组不接受任何治疗。我们的研究已证明，依那普利在开始透析的患者中至少在血液透析开始后的前12个月对保留残余肾功能有显著作用。有必要进行进一步研究，以调查ACEi对开始血液透析患者的残余肾功能以及发病率和死亡率的潜在长期影响。
